Vaxart, Inc. (VXRT)
|Net Income (ttm)||-46.93M|
|Trading Day||May 7|
|Day's Range||6.70 - 7.46|
|52-Week Range||2.23 - 24.90|
If it can reach the market of people that are hesitant to be vaccinated, yes.
Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.
Investors are excited about the company's experimental COVID-19 vaccine.
The shares of biotechnology concern Vaxart Inc (NASDAQ:VXRT) are up a whopping 11.5% to trade at $8.94 at last check , after the company announced its oral coronavirus vaccine produced positive phase 1 ...
Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained showed substantial CD8+ T-cell responses again...
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Vaxart oral vaccine induced higher CD8 + T-Cell responses than those seen with Moderna or Pfizer vaccines in comparative experiment conducted by the Company
Ocugen Inc. (NASDAQ: OCGN) and Vaxart Inc. (NASDAQ: VXRT) are moving Monday. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key varian...
VAXART, INC. (VXRT) delivered earnings and revenue surprises of -40.00% and -17.99%, respectively, for the quarter ended March 2021.
SOUTH SAN FRANCISCO, Calif., May 03, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by room-temperature stabl...
The biotech is slated to provide updates to investors on its vaccine development efforts next week.
SOUTH SAN FRANCISCO, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...
VXRT stock is up huge today as the company announces a coming webinar. Investors are turning bullish as they expect to hear promising news.
Vaxart Inc. (NASDAQ:VXRT) shares are trading sharply higher Tuesday after the stock was trending on StockTwits. On Monday, the company announced it will host a key opinion leader webinar on the importan...
Many people want to be vaccinated, but hardly anybody likes injections. Soon VXRT stock could surge as Vaxart offers a less invasive method.
These tiny stocks could pack big-time return potential, if analysts are correct.
SOUTH SAN FRANCISCO, Calif., April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...
Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.
It's a gamble, but the payoff might be worth the risk.
Sometimes, the huge potential gains of small biotechs are worth the risk.
Vaxart stock has declined by around 25% over the last month and currently trades at about $5.80 per share. While the recent sell-off in the clinical stage biotech is due to broader correction in technol...
Let's look at what some of the smartest investors are saying.
Vaxart Inc. (NASDAQ: VXRT) shares gained 2.69% Tuesday on increased volume, closing the session at $7.06. The stock was trending on StockTwits, and there was no company evident news to explain the volu...
If its oral vaccine technology comes to fruition, then answering that question is easy.
Vaxart stock dropped 16% over the last five trading days, significantly underperforming the S&P 500 which gained about 1% over the same period. The stock is also down by about 40% over the last month (t...
A flaw in the logic behind a big sell-off may lead to a big surprise sometime in 2021.
The clinical-stage vaccine-focused biotech recently offered investors a glimmer of hope about its COVID-19 candidate.
And let's take a look at the most overrated, the most promising, and the most under-the-radar coronavirus stocks too.
Vaxart's trial data disappointed -- but one bright spot could turn things around.
SOUTH SAN FRANCISCO, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet r...
There are plenty of entrants in the race to develop a Covid-19 vaccine, but distinct advantages mark VXRT stock as a worthy biotech holding. The post Vaxart Stock Remains a Buy as Unique Covid-19 Vaccin...
VAXART, INC. (VXRT) witnessed a jump in share price last session on above-average trading volume.
Vaxart stock (NASDAQ: VXRT) dropped -8% over the last five trading days and has underperformed the S&P 500 which remained roughly flat over the same period. The stock is also down by about -27% over the...
The short answer: maybe.
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by in...
Let's look at what short-sellers are saying and what science is saying.
In the latest trading session, VAXART, INC. (VXRT) closed at $6.79, marking a -0.73% move from the previous day.
VAXART, INC. (VXRT) closed the most recent trading day at $7.94, moving -1.85% from the previous trading session.
On Vaxart's (VXRT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its oral COVID-19 vaccine candidate, VXA-CoV2-1.
The choice isn't easy, but simplicity may be the answer.
The company can still produce returns without a COVID vaccine.
The short answer: Yes.
Biotech company Vaxart posted mixed phase 1 results for its tablet-based Covid-19 vaccine, causing its stock to decline by over 60% from last week's high. Although the vaccine was well tolerated and pro...
The once high-flying biotech stock has crashed.
The stock lost more than half its value in one trading session.
Hope for an oral COVID-19 vaccine remains alive.
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, wh... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, Vaxart's revenue was $4.05 million, a decrease of -58.97% compared to the previous year's $9.86 million. Losses were -$32.22 million, 72.8% more than in 2019.
According to 3 analysts, the average rating for Vaxart stock is "Strong Buy." The 12-month stock price forecast is 13.33, which is an increase of 85.14% from the latest price.